Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

被引：0

作者：

Karimi, Yasmin

Ghesquieres, Herve

Jurczak, Wojciech

Cheah, Chan

Clausen, Michael

Lugtenburg, Pieternella

Cunningham, David

Do, Young Rok

Lewis, David John

Gasiorowski, Robin

Kim, Tae Min

Van der Poel, Marjolein

Poon, Michelle Li Mei

Feldman, Tatyana A.

Linton, Kim M.

Sureda, Anna

Hutchings, Martin

Stirner, Mariana Cota

Sacchi, Mariana

Thieblemont, Catherine

机构：

[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA

[2] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[3] MSC Natl Res Inst Oncol, Krakow, Poland

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[7] Royal Marsden NHS Fdn Trust, Sutton, England

[8] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea

[9] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Plymouth, England

[10] Univ Sydney, Concord Hosp, Sydney, NSW, Australia

[11] Seoul Natl Univ Hosp, Seoul, South Korea

[12] Maastricht Univ, Med Ctr, Maastricht Dept Internal Med, Div Hematol GROW,Sch Oncol & Dev Biol, Maastricht, Netherlands

[13] Natl Univ Singapore Hosp, Singapore, Singapore

[14] Hackensack Univ, Hackensack Meridian Hlth, Med Ctr, Hackensack, NJ USA

[15] Christie NHS Fdn Trust, Manchester, England

[16] Manchester Canc Res Ctr, Manchester, England

[17] Univ Barcelona, Inst Catal Oncol, Hosp Duran & Reynals, IDIBELL,Hosp Llobregat, Barcelona, Spain

[18] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[19] AbbVie Inc, N Chicago, IL USA

[20] Genmab, Princeton, NJ USA

[21] Univ Paris, Hop St Louis, Assistance Publ & Hop Paris APHP, Hematooncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7525

引用

页数：1

共 50 条

[31] Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial
Zinzani, Pier Luigi
Ribrag, Vincent
Moskowitz, Craig H.
Michot, Jean-Marie
Kuruvilla, John
Balakumaran, Arun
Zhang, Yayan
Marinello, Patricia
Chlosta, Sabine
Gustafson, Eric
Shipp, Margaret A.
Armand, Philippe
BLOOD, 2016, 128 (22)
[32] Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
Belada, David
Christensen, Jacob Haaber
Drott, Kristina
Snauwaert, Sylvia
Brody, Joshua
Narkhede, Mayur
Offner, Fritz
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
Clausen, Michael Roost
BLOOD, 2021, 138
[33] 2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 7 - 9
[34] Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
Abrisqueta, Pau
Falchi, Lorenzo
Phillips, Tycel Jovelle
De Vos, Sven
Nijland, Marcel
Offner, Fritz
Bykhovski, Irina
Wu, Jun
Wang, Liwei
Rana, Ali
Cordoba, Raul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[35] Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial
Hutchings, Martin
Lugtenburg, Pieternella
Mous, Rogier
Clausen, Michael Roost
Chamuleau, Martine
Linton, Kim
Rule, Simon
Lopez, Juanita
Oliveri, Roberto S.
DeMarco, Dena
Elliott, Brian
Johnson, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S274 - S274
[36] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S473
[37] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
BLOOD, 2023, 142
[38] Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Shah, Nirav N.
Flinn, Ian
Kwon, Mi
Jaeger, Ulrich
Briones, Javier
Bachy, Emmanuel
Blaise, Didier
Boissel, Nicolas
Kato, Koji
Riedell, Peter A.
Frigault, Matthew J.
Shune, Leyla O.
Teshima, Takanori
Ciceri, Fabio
Fleming, Shaun A.
Ferrari, Silvia
Pearson, David
Whalen, Jeanne
Zia, Aiesha
Davis, Jaclyn
Masood, Aisha
Dickinson, Michael
Barba, Pere
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S532 - S533
[39] Durable Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated with Fimepinostat (CUDC-907): Combined Results from a Phase 1 and Phase 2 Study
Landsburg, Daniel
Ramchandren, Rod
Oki, Yasuhiro
Pagel, John
Lugtenburg, P. J.
Gharavi, Robert
Ma, Anna
Tuck, David
Barta, Stefan K.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S279 - S279
[40] Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step- up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell NonHodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study
Bartlett, Nancy L.
Giri, Pratyush
Budde, L. Elizabeth
Schuster, Stephen J.
Assouline, Sarit
Matasar, Matthew J.
Yoon, Sung-Soo
Canales, Miguel
Gutierrez, Norma C.
Fay, Keith
Cheah, Chan-Yoon
Marlton, Paula
Wiebking, Volker
Yin, Shen
To, Iris
Li, Chi-Chung
Huang, Huang
Zhou, Mingzhu
Penuel, Elicia
O'Hear, Carol
Sehn, Laurie H.
BLOOD, 2021, 138

← 1 2 3 4 5 →